Mapi - Pharma (Mapi - Pharma) Equity-to-Asset : 0.48 (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Mapi - Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2015 was $9.48 Mil. Mapi - Pharma's Total Assets for the quarter that ended in Jun. 2015 was $19.78 Mil.

The historical rank and industry rank for Mapi - Pharma's Equity-to-Asset or its related term are showing as below:

MAPI's Equity-to-Asset is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.58
* Ranked among companies with meaningful Equity-to-Asset only.

Mapi - Pharma Equity-to-Asset Historical Data

The historical data trend for Mapi - Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Equity-to-Asset Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Equity-to-Asset

0.62

0.64

0.55

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Equity-to-Asset	0.62	0.64	-	0.55	0.48

Competitive Comparison of Mapi - Pharma's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Equity-to-Asset falls into.

Mapi - Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Mapi - Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2014 is calculated as

Equity to Asset (A: Dec. 2014 )	=	Total Stockholders Equity	/	Total Assets
	=	5.457	/	9.858
	=

Mapi - Pharma's Equity to Asset Ratio for the quarter that ended in Jun. 2015 is calculated as

Equity to Asset (Q: Jun. 2015 )	=	Total Stockholders Equity	/	Total Assets
	=	9.479	/	19.779
	=

Mapi - Pharma (NAS:MAPI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Mapi - Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.